REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design

被引：0

作者：

Ghorani, Ehsan ^{[1
]}

Quartagno, Matteo ^{[2
]}

Blackhall, Fiona ^{[3
]}

O'Brien, Mary ^{[4
]}

Ottensmeier, Christian ^{[5
,6
]}

Pizzo, Elena ^{[7
]}

Spicer, James ^{[8
]}

Gilbert, Duncan ^{[2
]}

Baker, Alex ^{[9
]}

Badman, Philip ^{[9
]}

Milner-Watts, Charlotte ^{[4
]}

d'Arienzo, D. Paolo

Dangoor, Adam ^{[10
]}

Adhikaree, Jason ^{[11
]}

Evans, Joanne ^{[12
]}

Leite, Pollyanna ^{[12
]}

Keni, Manjusha ^{[13
]}

Steele, Nicola ^{[14
,15
]}

Gomes, Fabio ^{[3
]}

Gomez-Randulfe, Igor ^{[3
]}

Belitei, Petru ^{[16
]}

Stewart, Grant ^{[17
]}

Barrie, Colin ^{[18
]}

Geldart, Tom ^{[19
]}

Jain, Pooja ^{[20
]}

Justin, Liu K. H. ^{[20
]}

Zubairi, Ishtaiq ^{[14
]}

Muthukumar, Dakshinamoorthy ^{[21
]}

Gray, Lucy ^{[21
]}

Treece, Sarah ^{[22
]}

Aleksic, Aleksandar ^{[23
,24
]}

Tsaknis, Georgios ^{[24
]}

Rathbone, Emma ^{[25
]}

Shaw, Paul ^{[26
]}

Tarver, Kathryn ^{[27
]}

Mahesh, K. B. ^{[2
]}

Seckl, Michael J. ^{[1
]}

机构：

[1] Imperial Coll London, Charing Cross Hosp, Dept Med Oncol, London, England

[2] UCL, Inst Clin Trials & Methodol, MRC Clin Trials Inst, London, England

[3] Christie NHS Fdn Trust, Manchester, England

[4] Royal Marsden NHS Fdn Trust, Sutton, England

[5] Clatterbridge Canc Ctr NHS Fdn Trust, Liverpool, England

[6] Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool, England

[7] UCL, Dept Appl Hlth Res, London, England

[8] Kings Coll London, Guys Hosp, London, England

[9] Imperial Coll London, Dept Surg & Canc, Imperial Clin Trials Unit Canc, London, England

[10] Univ Hosp Bristol NHS Fdn Trust, Bristol, England

[11] Nottingham Univ Hosp NHS Trust, Nottingham, England

[12] Imperial Coll Healthcare NHS Trust, London, England

[13] Univ Hosp Derby & Burton NHS Fdn Trust, Derby, England

[14] NHS Greater Glasgowand Clyde, Glasgow, Scotland

[15] NHS Forth Valley, Larbert, Scotland

[16] Royal Devon Univ Healthcare NHS Fdn Trust, Exeter, England

[17] Royal Cornwall Hosp NHS Trust, Truro, England

[18] NHS Lothian, Edinburgh, Scotland

[19] Univ Hosp Dorset NHS Fdn Trust, Bournemouth, England

[20] Leeds Teaching Hosp NHS Trust, Leeds, England

[21] East Suffolk & North Essex NHS Fdn Trust, Colchester, England

[22] North West Anglia NHS Fdn Trust, Peterborough, England

[23] Northampton Gen Hosp NHS Trust, Northampton, England

[24] Kettering Gen Hosp NHS Fdn Trust, Kettering, England

[25] Calderdale & Huddersfield NHS Fdn Trust, Huddersfield, England

[26] Velindre Univ NHS Trust, Cardiff, Wales

[27] Barking Havering & Redbridge Univ Hosp NHS Trust, London, England

来源：

LUNG CANCER | 2024年 / 190卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

204

引用

页数：1

共 50 条

[31] Gefitinib: Phase II and III results in advanced non-small cell lung cancer
Kelly, K
Averbuch, S
SEMINARS IN ONCOLOGY, 2004, 31 (01) : 93 - 99
[32] TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)
Zhou, C.
Levy, B. P.
Sands, J.
Parakh, S.
Sugawara, S.
Syrigos, K.
Ahn, J. S.
Zhao, M.
Lin, C. -C.
Felip, E.
Cappuzzo, F.
Reck, M.
Yang, J. C. H.
Joseph, R.
Rawat, S.
Xie, J.
Okamoto, I.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S327 - S328
[33] Randomized phase III study of Gemcitabine/cisplatin versus mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer (NSCLC)
Scagliotti, G
Crino, L
Conte, PF
Rinaldi, M
De Marinis, F
Gridelli, C
ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
[34] SUNITINIB (SU) IN COMBINATION WITH ERLOTINIB (E) FOR THE TREATMENT OF ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE III STUDY
Scagliotti, G. V.
Krzakowski, M.
Szczesna, A.
Strausz, J.
Makhson, A.
Reck, M.
Tye, L.
Selaru, P.
Chao, R. C.
Govindan, R.
ANNALS OF ONCOLOGY, 2010, 21 : 3 - 4
[35] Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC).
Demarinis, F.
Paul, S.
Hanna, N.
Tsao, T. Chang Yao
Adachi, S.
Lim, H. L.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 397S - 397S
[36] Phase III study of neo-adjuvant chemotherapy in resectable non-small cell lung cancer (NSCLC)
Depierre, A
Milleron, B
Moro, D
Quoix, E
Lebeau, B
Chastang, C
Braun, D
Janicot, H
Paillot, N
Gouva, S
Coudert, B
Breton, JL
Lemarie, E
Lebas, FX
Coetmeur, D
Thiberville, L
Brehot, JM
EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1053 - 1053
[37] Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC).
Miller, AA
Case, D
Atkins, J
Giguere, J
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 649S - 649S
[38] Phase II study of vinorelbine (VNR) and gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC)
Firvida, JL
Rodriguez, R
Sabin, P
Castellanos, J
Mata, JG
Salgado, M
Vazquez, S
Lazaro, M
Delgado, FM
ANNALS OF ONCOLOGY, 1998, 9 : 97 - 97
[39] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.
Park, Keunchil
Cho, Eun Kyung
Kang, Jin Hyoung
Han, Ji-Youn
Lee, Jong Seok
Kim, Dong-Wan
Kim, Sang-We
Cho, Byoung Chul
Min, Young Joo
Lee, Ki Hyeong
Kim, Joo-Hang
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
[40] Phase I study of gemcitabine (GEM) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC).
Kawabata, S
Oka, M
Fukuda, M
Kinoshita, A
Fukuda, M
Nagashima, S
Nakamura, Y
Nakano, H
Soda, H
Kohno, S
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 688S - 688S

← 1 2 3 4 5 →